Reneo reports Q3 net loss $13.0M, >80% enrolled in pivotal STRIDE study

OnKure Therapeutics, Inc.

2022-Q3 EPS reported -$1.57

Net loss of $13.0M ($0.53 per share) vs $12.7M ($0.52) in Q3 2021.
Cash, equivalents & short-term investments total $116M as of Sept 30, 2022.
Over 80% enrollment in pivotal STRIDE study for PMM with mtDNA defects; topline data expected Q4 2023.
Positive Phase 1b results in LC-FAOD patients; planning Phase 2 study.
FDA and EMA confirmed positive data from STRIDE/STRIDE AHEAD could support registration.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

OnKure Therapeutics, Inc. reported the three months ended September 30, 2022 results: net income $13.0 million, EPS $0.53 per share.

Period: the three months ended September 30, 2022
Net income: $13.0 million
EPS: $0.53 per share
Result: reported results

Exact text from the filing

The Company reported a net loss of $13.0 million, or $0.53 per share, for the three months ended September 30, 2022

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023234

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.